

Update on Funding Strategy

Universal Biosensors, Inc. (ASX: UBI) (**Company**) provides an update regarding its funding strategy and the non-binding term sheet announced on 2 July 2025 with its substantial securityholder, Viburnum Funds Pty Ltd (**Viburnum**) in respect of a proposed secured loan facility and the update on the funding strategy provided on 7 August 2025.

At this stage, no binding commitment has been made by Viburnum in relation to the proposed funding structures. Completion of the conditions of the funding structures at this stage have not been met. To facilitate the ongoing discussions, Viburnum has agreed to extend the due diligence period under the non-binding term sheet previously announced by one week to Friday, 22 August 2025.

The Company will provide a further market update, including a revised indicative timetable, once the terms of the revised funding transaction has been finalised with Viburnum.

End

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

For further information contact:
Graham McLean
Chair
+61 (0) 416 190 764

About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.